Griffith A H
Br Med J. 1978 Apr 1;1(6116):809-15. doi: 10.1136/bmj.1.6116.809.
Pertussis vaccines vary in quality, safety, and efficacy according to the production strains of Bordetella pertussis, the method of manufacture, and quality control procedures. It is therefore not justifiable to combine information on the incidence, nature, and severity of reactions after all manufacturers' pertussis vaccines as if they were a single product. Attempts were made to collect information on all suspected cases of severe reactions that occurred after administration of about 15 million doses of Wellcome pertussis vaccines in the United Kingdom and Northern Ireland from 1964 to mid-1977. Altogether six deaths, six neurological reactions with sequelae, and 17 convulsions without sequelae were reported, but some were clearly not attributable to the vaccine, while, in other cases, the available information was inadequate for assessing the role of vaccination. Neurological disorders, similar to those reported in a few children after pertussis vaccination, occur unexpectedly in apparently healthy infants at the recommended age for immunisation, so chance association between vaccination and these events can be expected in some children. The Joint Committee on Vaccination and Immunisation has made several recommendations aimed at reducing severe reactions after pertussis vaccination. These include replacing plain vaccine with aluminium-adsorbed vaccine, but there is no clear evidence that the aluminium-adsorbed vaccine produces fewer reactions than the plain.There are difficulties enough in deciding the cause of events that occur after vaccination, since these reactions often occur naturally in children of vaccination age. The task is made even harder by the assumption that various manufacturers' vaccines are the same and the lack of information available to manufacturers about cases in which their vaccine has been implicated. Information on vaccines administered is entered on immunisation records cards; it should be used and referred to if reactions occur.
百日咳疫苗在质量、安全性和有效性方面因百日咳博德特氏菌的生产菌株、制造方法和质量控制程序而异。因此,将所有制造商的百日咳疫苗接种后反应的发生率、性质和严重程度信息汇总在一起,就好像它们是单一产品一样,是不合理的。1964年至1977年年中,在英国和北爱尔兰,有人试图收集有关接种约1500万剂威康百日咳疫苗后发生的所有疑似严重反应病例的信息。总共报告了6例死亡、6例伴有后遗症的神经反应和17例无后遗症的惊厥,但有些显然与疫苗无关,而在其他情况下,现有信息不足以评估疫苗接种的作用。在推荐的免疫接种年龄,看似健康的婴儿会意外出现与少数儿童接种百日咳疫苗后报告的类似神经疾病,因此预计在一些儿童中,疫苗接种与这些事件之间会存在偶然关联。疫苗接种和免疫联合委员会提出了几项旨在减少百日咳疫苗接种后严重反应的建议。这些建议包括用吸附铝的疫苗取代普通疫苗,但没有明确证据表明吸附铝的疫苗产生的反应比普通疫苗少。确定接种疫苗后发生的事件原因存在诸多困难,因为这些反应在接种疫苗年龄的儿童中经常自然发生。由于假定各制造商的疫苗相同,且制造商缺乏有关其疫苗涉及病例的可用信息,这项任务变得更加艰巨。接种疫苗的信息会记录在免疫接种记录卡上;如果发生反应,应使用并参考这些信息。